Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.5.3 to v3.5.4. This is a minor update to the page's revision history metadata.
    Difference
    0.0%
    Check dated 2026-05-17T09:45:04.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    27 days ago
    No Change Detected
  5. Check
    34 days ago
    Change Detected
    Summary
    The page footer/version label was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” reflecting a site release change without altering the study information presented.
    Difference
    0.0%
    Check dated 2026-04-25T18:45:24.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    Page revision updated: v3.5.0 removed, v3.5.2 added.
    Difference
    0.0%
    Check dated 2026-04-18T13:36:01.000Z thumbnail image
  7. Check
    55 days ago
    Change Detected
    Summary
    Added Padova, Italy and removed Padua, Italy from the Locations list.
    Difference
    0.0%
    Check dated 2026-04-04T06:00:37.000Z thumbnail image
  8. Check
    70 days ago
    Change Detected
    Summary
    Napoli, Italy was replaced with Naples, Italy in the location listings, and revision tags were updated to v3.5.0 (added) and v3.4.3 (removed).
    Difference
    0.0%
    Check dated 2026-03-21T00:44:54.000Z thumbnail image
  9. Check
    84 days ago
    Change Detected
    Summary
    Revision note updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-06T19:49:12.000Z thumbnail image

Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.